[关键词]
[摘要]
目的 探讨丹红注射液联合乙酰谷酰胺注射液治疗急性脑梗死恢复期的临床疗效。方法 选取2020年1月—2021年8月在濮阳市人民医院确诊并治疗的136例脑梗死恢复期患者,按照随机数字表法,将患者分为对照组和治疗组,每组各68例。对照组患者静脉滴注乙酰谷酰胺注射液,0.6 g加入5%葡萄糖注射液250 mL中,1次/d。治疗组在对照组基础上静脉滴注丹红注射液,40 mL加入5%葡萄糖注射液250 mL中,1次/d。两组患者均连续治疗2周。观察两组患者的临床疗效,比较两组治疗前后相关评分、颈总动脉和大脑中动脉血流动力学指标、氧化应激指标和血管新生促进因子指标的变化情况。结果 治疗后,治疗组总有效率为95.59%,显著高于对照组的86.76%(P<0.05)。治疗后,两组患者的NIHSS评分、mRS评分均较治疗前有显著下降,而FMA评分均明显上升(P<0.05),且治疗后,治疗组患者NIHSS、FMA、mRS评分改善优于对照组(P<0.05)。治疗后,两组患者颈总动脉、大脑中动脉收缩期峰值血流速度(PSV)、舒张期末血流速度(EDV)水平均较治疗前显著提高,但搏动指数(PI)均显著下降(P<0.05),且治疗后,治疗组患者血流动力学参数水平改善优于对照组(P<0.05)。治疗后,两组患者谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)水平均较治疗前显著提高,8-OHdG8-羟基脱氧鸟苷(8-OHdG)、氧化型低密度脂蛋白(ox-LDL)水平均显著下降(P<0.05),且治疗后,治疗组患者氧化应激水平改善优于对照组(P<0.05)。治疗后,两组患者血管内皮细胞生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、转化生长因子β1(TGF-β1)水平较治疗前均显著提高(P<0.05),且治疗后治疗组患者血管新生促进因子指标改善更明显(P<0.05)。结论 丹红注射液联合乙酰谷酰胺注射液可治疗急性脑梗死具有良好的临床疗效,可改善患者的神经功能缺损程度,提高运动功能,调控氧化应激反应,促进血管新生,值得临床广泛应用。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Danhong Injection combined with Aceglutamide Injection in treatment of acute cerebral infarction convalescence. Methods A total of 136 convalescence patients with cerebral infarction diagnosed and treated in Puyang People's Hospital from January 2020 to August 2021 were selected and divided into control group and treatment group according to random number method, with 68 cases in each group. Patients in the control group were iv administered with Aceglutamide Injection, 0.6 g was added into 5% glucose injection 250 mL, once daily. Patients in the treatment group were iv administered with Danhong Injection on the basis of the control group, 40 mL was added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of correlation scores, blood flow dynamics indexes, oxidative stress indexes and angiogenesis promoting factor indexes of common carotid artery and middle cerebral artery were compared before and after treatment. Results After treatment, the total effective rate in the treatment group was 95.59%, significantly higher than 86.76% in the control group (P < 0.05). After treatment, NIHSS and mRS scores in two groups were significantly decreased compared with before treatment, while FMA scores were significantly increased (P < 0.05), and NIHSS, FMA and mRS scores in the treatment group were improved better than those in the control group (P < 0.05). After treatment, two groups of patients with carotid artery, middle cerebral artery peak systolic velocity (PSV), final diastolic blood flow velocity (EDV) level was significantly increased, the but pulsation index (PI) were significantly decreased (P< 0.05), and after treatment, the treatment group patients hemodynamic parameters level improvement is better than that of control group (P< 0.05). After treatment, the levels of glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD) in two groups were significantly increased compared with before treatment, but the levels of 8-OHdG and oxidized low-density lipoprotein (ox-LDL) were significantly decreased (P < 0.05). The improvement of oxidative stress level in treatment group was better than that in control group (P < 0.05). After treatment, the levels of vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor β1 (TGF-β1) in two groups were significantly increased compared with before treatment (P < 0.05), and the improvement of angiogenesis promoting factor indexes in treatment group was more obvious (P < 0.05). Conclusions Danhong Injection combined with Aceglutamide Injection has good clinical effect in treatment of acute cerebral infarction convalescence, and can improve the degree of neurological impairment, improve motor function, regulate oxidative stress response and promote angiogenesis, which is worthy of widespread clinical application.
[中图分类号]
R971
[基金项目]